Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2007

01.02.2007

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

verfasst von: Michael D’Angelica, MD, Peter Kornprat, MD, Mithat Gonen, PhD, Ki-Young Chung, MD, William R. Jarnagin, MD, FACS, Ronald P. DeMatteo, MD, FACS, Yuman Fong, MD, FACS, Nancy Kemeny, MD, Leslie H. Blumgart, MD, FACS, FRCS, Leonard B Saltz, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Bevacizumab (bev) is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection.

Methods

Computerized pharmacy records were used to identify all patients who received bev between January 2004 and June 2005. Patients who underwent hepatectomy for colorectal metastases and received bev within 12 weeks of surgery were identified and compared with a group of matched historical controls.

Results

Thirty-two patients underwent hepatic resection of colorectal cancer metastases and received bev within the specified perioperative period. Sixteen patients received bev before surgery and 24 received bev after surgery. A subset of eight patients received bev both before and after surgery. The median time between bev administration and surgery was 6.9 weeks before (range, 3–15 weeks) and 7.4 weeks after (range, 5–15 weeks). Perioperative complications occurred in 13 patients (40.6%), two of which were considered major complications. There was no statistically significant difference in perioperative morbidity and severity of complications when compared with a set of matched controls.

Conclusions

Clinical experience thus far does not indicate a statistically significantly increased risk of perioperative complications with the incorporation of bev into pre- and/or postoperative treatment paradigms. Given the long half-life of bev and the potential for anti-VEGF therapy to impede wound healing and/or liver regeneration, we continue to favor a window of 6 to 8 weeks between bev administration and surgery.
Literatur
1.
Zurück zum Zitat Fong Y, Fortner J, Sun R, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–30PubMedCrossRef Fong Y, Fortner J, Sun R, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–30PubMedCrossRef
2.
Zurück zum Zitat Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1995; 19:59–71PubMedCrossRef Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1995; 19:59–71PubMedCrossRef
3.
Zurück zum Zitat Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905–14PubMedCrossRef Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905–14PubMedCrossRef
4.
Zurück zum Zitat Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23:4888–96PubMedCrossRef Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23:4888–96PubMedCrossRef
5.
Zurück zum Zitat Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229–37PubMedCrossRef Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229–37PubMedCrossRef
6.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335–42PubMedCrossRef
7.
Zurück zum Zitat Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) Study E3200 (abstract 2). Proc Am Soc Clin Oncol 2005; 23:16S Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) Study E3200 (abstract 2). Proc Am Soc Clin Oncol 2005; 23:16S
9.
Zurück zum Zitat Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60–5PubMedCrossRef Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60–5PubMedCrossRef
10.
Zurück zum Zitat Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706–12PubMedCrossRef Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706–12PubMedCrossRef
11.
Zurück zum Zitat Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005; 23:4853–5PubMedCrossRef Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005; 23:4853–5PubMedCrossRef
12.
Zurück zum Zitat Scappaticci F, Fehrenbacher L, Cartwright J, et al. Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery (abstract 3530). Proc Am Soc Clin Oncol 2004; 22:14S Scappaticci F, Fehrenbacher L, Cartwright J, et al. Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery (abstract 3530). Proc Am Soc Clin Oncol 2004; 22:14S
13.
Zurück zum Zitat Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection. Ann Surg 2002; 236:397–407PubMedCrossRef Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection. Ann Surg 2002; 236:397–407PubMedCrossRef
14.
Zurück zum Zitat Couinaud C. Bases anatomiques des hepatectomies gauche et droite reglees. J Chir 1954; 70:933–66 Couinaud C. Bases anatomiques des hepatectomies gauche et droite reglees. J Chir 1954; 70:933–66
15.
Zurück zum Zitat Martin RC, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg 2002; 235:803–13PubMedCrossRef Martin RC, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg 2002; 235:803–13PubMedCrossRef
16.
Zurück zum Zitat Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502–8PubMedCrossRef Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502–8PubMedCrossRef
17.
Zurück zum Zitat Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR-2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6:553–63PubMed Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR-2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6:553–63PubMed
18.
Zurück zum Zitat Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 7:58–62CrossRef Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 7:58–62CrossRef
19.
Zurück zum Zitat Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30:39–50PubMed Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30:39–50PubMed
20.
Zurück zum Zitat Furnus CC, Inda AM, Andrini LB, et al. Chronobiology of the proliferative events related to angiogenesis in mice live regeneration after partial hepatectomy. Cell Biol Int 2003; 27:383–6PubMedCrossRef Furnus CC, Inda AM, Andrini LB, et al. Chronobiology of the proliferative events related to angiogenesis in mice live regeneration after partial hepatectomy. Cell Biol Int 2003; 27:383–6PubMedCrossRef
21.
Zurück zum Zitat Kraizer Y, Mawasi N, Saegal J, et al. Vascular endothelial growth factor and angiopoetin in liver regeneration. Biochem Biophys Res Commun 2001; 287:209–15PubMedCrossRef Kraizer Y, Mawasi N, Saegal J, et al. Vascular endothelial growth factor and angiopoetin in liver regeneration. Biochem Biophys Res Commun 2001; 287:209–15PubMedCrossRef
22.
Zurück zum Zitat LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299:890–3PubMedCrossRef LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299:890–3PubMedCrossRef
23.
Zurück zum Zitat Haroon Z, Amin K, Saito W, et al. SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther 2002; 1:121–6PubMed Haroon Z, Amin K, Saito W, et al. SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther 2002; 1:121–6PubMed
24.
Zurück zum Zitat Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21:3542PubMedCrossRef Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21:3542PubMedCrossRef
25.
Zurück zum Zitat Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 2005; 23:2574–6PubMedCrossRef Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 2005; 23:2574–6PubMedCrossRef
26.
Zurück zum Zitat Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti–vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843–50PubMed Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti–vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843–50PubMed
27.
Zurück zum Zitat Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237:860–70PubMedCrossRef Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237:860–70PubMedCrossRef
Metadaten
Titel
Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study
verfasst von
Michael D’Angelica, MD
Peter Kornprat, MD
Mithat Gonen, PhD
Ki-Young Chung, MD
William R. Jarnagin, MD, FACS
Ronald P. DeMatteo, MD, FACS
Yuman Fong, MD, FACS
Nancy Kemeny, MD
Leslie H. Blumgart, MD, FACS, FRCS
Leonard B Saltz, MD
Publikationsdatum
01.02.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9074-0

Weitere Artikel der Ausgabe 2/2007

Annals of Surgical Oncology 2/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.